—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...

Company Overview - BioCryst Pharmaceuticals (BCRX) is expected to report a quarterly loss of $0.19 per share, reflecting a year-over-year change of +20.8% [2] - Revenues are anticipated to be $98.27 million, which is a 19.1% increase from the same quarter last year [2] - The Most Accurate Estimate for BioCryst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.62% [5] Earnings Expectations - The upcoming earnings report is scheduled for August 5, and the stock price may react positively if actual results exceed expectations [1] - Conversely, if the results fall short, the stock may decline [1] - The consensus EPS estimate has been revised 2.7% lower over the last 30 days, indicating a reassessment by analysts [2] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.23 per share but actually reported a loss of $0.17, resulting in a surprise of +26.09% [7] - Over the past four quarters, BioCryst has beaten consensus EPS estimates three times [7] Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to post a loss of $0.10 per share, indicating a year-over-year change of -25% [9] - Ardelyx's revenue is projected to be $55.73 million, up 149.6% from the previous year [9] - The consensus EPS estimate for Ardelyx has been revised 14% higher in the last 30 days, resulting in a positive Earnings ESP of 3.92% [9]

Group 1 - BioCryst Pharmaceuticals will report its second quarter 2024 financial results on August 5, 2024 [1] - The management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update [1] - The live call can be accessed by domestic and international callers through specific dialing numbers [1] Group 2 - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with complement-mediated and other rare diseases [2] - The company utilizes structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics [2] - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of therapies [2]

Olivier Le Moal/iStock via Getty Images BioCryst Pharmaceuticals (NASDAQ:BCRX) is a biotechnology company developing complement-mediated and rare disease treatments. The company leverages a structure-guided drug design process that integrates biology and medicinal chemistry to generate therapeutics for diseases with unmet medical needs. BCRX has Orladeyo (berotralstat), which represents 95.8% of total revenues, and royalties from Rapivab (Peramivir) injections. Unfortunately, BCRX is heavily leveraged, ...

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings potential and likely favorable impact on its stock price [1][2]. Earnings Outlook - The upgrade reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. - For the fiscal year ending December 2024, BioCryst is expected to earn -$0.65 per share, representing a 35% change from the previous year's reported figure [5]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for BioCryst has increased by 4.8%, indicating a positive revision trend [5]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [4]. Institutional Investor Influence - Changes in earnings estimates are closely correlated with stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [3]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying or selling actions that influence stock prices [3]. Market Positioning - The upgrade to Zacks Rank 1 places BioCryst in the top 5% of Zacks-covered stocks, suggesting a strong potential for near-term price appreciation [7].

Core Viewpoint - BioCryst Pharmaceuticals has received approval from Peru's DIGEMID for ORLADEYO® (berotralstat) as a prophylactic treatment for hereditary angioedema (HAE) in patients aged 12 and older, marking a significant expansion in treatment options for HAE in the pan-Latin America region [1][2]. Group 1: Product Information - ORLADEYO® (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in adults and pediatric patients aged 12 years and older, with a recommended dosage of one capsule per day [3]. - The drug functions by decreasing the activity of plasma kallikrein, which is involved in the pathophysiology of HAE [3]. - ORLADEYO has already received regulatory approvals in Chile, Argentina, Brazil, and Mexico, indicating a growing acceptance in the Latin American market [2]. Group 2: Collaboration and Commercialization - BioCryst has an exclusive collaboration with Pint Pharma GmbH for the registration and promotion of ORLADEYO in the pan-Latin America region, with Pint responsible for obtaining and maintaining marketing authorizations [2]. - The partnership aims to enhance the availability of ORLADEYO for patients in need of new treatment options across Latin America [1]. Group 3: Safety and Efficacy - The safety and effectiveness of ORLADEYO for treating acute HAE attacks have not been established, and it is not recommended for such use [5]. - Common adverse reactions observed in patients taking ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease, with a noted increase in QT prolongation at dosages higher than 150 mg [6][5]. - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [6]. Group 4: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing therapies for rare diseases, leveraging expertise in structure-guided drug design to create innovative treatments [8].

Core Insights - BioCryst Pharmaceuticals announced new data on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment to be presented at the EAACI meeting in Valencia, Spain from May 31 to June 3, 2024 [1] Group 1: Product Information - ORLADEYO® (berotralstat) is the first and only oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older [2] - The drug works by decreasing the activity of plasma kallikrein, with a recommended dosage of one capsule per day [2] Group 2: Clinical Data Presentation - Two abstracts will be presented at the EAACI meeting: 1. Adverse Health Outcomes and Patient and Physician Perspectives of Attenuated Androgen Use in HAE [1] 2. Effectiveness and Safety of Berotralstat in Patients with HAE with Normal C1 Inhibitor: A European Case Series [1] Group 3: Safety Information - ORLADEYO is indicated for prophylaxis to prevent HAE attacks but not for the treatment of acute attacks [3][4] - Common adverse reactions include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5]

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are p ...

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and Outcomes Rese ...